Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note published on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. HC Wainwright reiterated a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th. Mizuho cut their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Finally, Barclays dropped their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday, December 23rd. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Revance Therapeutics presently has a consensus rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Price Performance

Shares of Revance Therapeutics stock opened at $3.64 on Wednesday. The firm has a fifty day moving average price of $3.41 and a 200 day moving average price of $4.60. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.56.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. As a group, equities analysts expect that Revance Therapeutics will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Revance Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FORA Capital LLC acquired a new stake in shares of Revance Therapeutics in the third quarter valued at about $54,000. Creative Planning acquired a new position in shares of Revance Therapeutics during the 3rd quarter worth about $56,000. Vanguard Personalized Indexing Management LLC purchased a new position in Revance Therapeutics in the 2nd quarter valued at about $33,000. Accredited Investors Inc. acquired a new stake in Revance Therapeutics in the 3rd quarter worth about $67,000. Finally, Hsbc Holdings PLC purchased a new stake in Revance Therapeutics during the 2nd quarter worth approximately $38,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.